Clinical trials: Alzheimer Disease, Early Onset
Alzheimer's Disease, Dementia
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of…
- Conditions
- Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
- Trial name
- DIAN-TU (NCT06384573)
- Testing
- lecanemab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA)
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
- Conditions
- Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease
- Trial name
- NCT02740634
- Testing
- F-18 AV 1451, C-11 PiB
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Alzheimer Disease (AD)
Study of Neural Stem Cell-Derived Exosomes in Moderate-to-Severe Early-Onset Alzheimer's Disease
This is an open-label, single-center, phase I clinical study in patients with moderate-to-severe early-onset Alzheimer's disease.
- Trial name
- NCT07554872
- Testing
- Neural Stem Cell-Derived Exosomes
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Mental Health Center
Alzheimer Disease, Early Onset
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase 3 study comparing LIPUS-Brain transcranial low-intensity pulsed-wave ultrasound device to placebo in patients with Early Alzheimer's Disease.
- Trial name
- NCT05983575
- Testing
- LIPUS-Brain
- Where
- 19 sites in Japan
- Volunteers
- 220 people
- Sponsor
- Sound Wave Innovation CO., LTD.
Alzheimer Disease, Early Onset, Posterior Cortical Atrophy
MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY
Patients with Alzheimer's disease and with early onset of symptoms (<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground.
- Trial name
- PET-AL (NCT04150198)
- Testing
- TEP/IRM
- Where
- 2 sites in France
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease
Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease
Alzheimer's disease (AD) is the leading neurodegenerative disease of aging characterized by multiple cognitive impairments. Given the recent failures of disease-modifying drugs, the current focus is on preventing or mitigating…
- Conditions
- Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
- Trial name
- NCT04122001
- Testing
- Active, in-person HD-tDCS or active remote tDCS, Word List Learning Intervention (WordLLI)
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Early-Onset Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOAD
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of a single dose and multiple doses of ALN-APP administered by intrathecal (IT) injection in adult patients with…
- Trial name
- NCT05231785
- Testing
- ALN-APP
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Alnylam Pharmaceuticals
Cognitive Impairment, Alzheimer Disease, Early Onset
Juice Plus Supplement Clinical Trial
The study is designed to determine whether encapsulated fruit and vegetable juice concentrates can improve biological indicators of cognitive and multiple dimensions of memory and learning.
- Conditions
- Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
- Trial name
- NCT04656860
- Testing
- Juice Plus+
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Alabama, Tuscaloosa
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease
Early Onset Alzheimer's Disease Genomic Study
The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis.
- Trial name
- TGen (NCT03645993)
- Testing
- Genetic Testing
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor Research Institute
Frailty, Cognitive Impairment
A Practical Platform for In-Home Remote Monitoring of Cognitive Frailty
Cognitive frailty, characterized by the coexistence of physical frailty and cognitive impairment, is a robust indicator of cognitive decline.
- Conditions
- Frailty, Cognitive Impairment, Dementia, Cognitive Impairment, Mild
- Trial name
- NCT05754021
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Baylor College of Medicine
Early Onset Alzheimer Disease, Alzheimer Disease
Sleep Apnea in Early to Mid-Stage Alzheimer's Disease
Obstructive sleep apnea (OSA) is much more common in the elderly than in the young; the latest studies show prevalence between 45% and 62% in individuals over 60.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Obstructive Sleep Apnea Syndromes
- Trial name
- AZAP (NCT01400542)
- Testing
- CPAP Treatment, No treatment
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Alzheimer Disease, Early Onset
Effects of a Widely Used Vaccine Adjuvant in Subjects With Early Alzheimer's Disease Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients With Early Alzheimer's Disease - ADVANCE
The purpose of this randomized, placebo-controlled phase 2b study is to prospectively evaluate AD04's potential as a disease-modifying drug in AD.
- Trial name
- NCT07107074
- Testing
- AD04
- Where
- 3 sites in Austria, Poland
- Volunteers
- 122 people
- Sponsor
- ADvantage Therapeutics
Alzheimer Disease, Early Onset, Parkinson Disease
Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity
The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal…
- Trial name
- NODAL (NCT06080659)
- Testing
- fMRI, CONFMEM
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Alzheimer Disease, Early-Onset
Examining Neuroinflammation in AlzHeimer's
Alzheimer disease (AD) is a neurodegenerative disorder with a poorly understood pathology. It is an irreversible progressive brain disease that slowly deteriorates memory, thinking and behavior.
- Trial name
- ENHANCE (NCT03548883)
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AdventHealth
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Alzheimer Disease, Early Onset
MIMA Pilot Study: MIcrostructure of the Medial Temporal Lobe in Early Alzheimer's Disease
Patients with Mild Cognitive Impairment (MCI) or Subjective Cognitive Decline (SCD) may or may not develop Alzheimer's disease (AD) dementia.
- Trial name
- MIMA-P (NCT06099587)
- Testing
- high-resolution diffusion MRI
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Rennes University Hospital
Alzheimer Disease, Early Onset
Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease
The objective of this project is to conduct research and a pilot study to demonstrate the potential clinical impact and technical feasibility of a socially-assistive robot, called Ryan Companionbot (hereafter Ryan), for life…
- Trial name
- NCT05052866
- Testing
- Social Robot
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- DreamFace Technologies, LLC
Alzheimer Disease, Early Onset
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
- Trial name
- TargetTau-1 (NCT06268886)
- Testing
- BMS-986446
- Where
- 176 sites in United States, Australia and 8 more
- Volunteers
- 310 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Engagement 2.0 Forms of Consent for Data (re-)Use
The objective of this qualitative study is to create a better understanding of patients' mental model of health data engagement interfaces and tools (such as Dynamic Consent).
- Trial name
- ENGAGE (NCT05229978)
- Testing
- Showing an existing Dynamic Consent (computer interface) as prompt
- Where
- Belgium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel